Clinical Trial Update: This Study is to Compare the Efficacy of ZD6474 and ZD1839 in Subjects With NSCLC. [Phase 2]

View source ↗

Summary

A Phase 2 trial comparing the efficacy of ZD6474 (vandetanib) and ZD1839 (gefitinib) in non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ZD1839 (Gefitinib)
• ZD6474 (vandetanib)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 2 | Status: COMPLETED